We offer a complete range of chromatography resins for the purification of mAbs, bispecific antibodies, and ADCs. This includes Protein A affinity resins for initial capture, as well as ion exchange and hydrophobic interaction media for intermediate purification and polishing to remove aggregates and host cell proteins.
Application Description
-
01【Case Analysis】Decoding the Stealth of Bispecific Antibody Fragment Impurities
Bispecific antibodies (BsAbs) demonstrate significant therapeutic potential in tumor immunotherapy and other fields due to their ability to simultaneously target two different epitopes. However, their complex heterodimeric structure can generate multiple fragment impurities during production, including homodimers, half-antibodies (monovalent antibodies), low-molecular-weight degradation fragments, and high-molecular-weight aggregates. These impurities can significantly impact the biological activity, stability, safety, and efficacy of the drug, and may even pose immunogenicity risks. Therefore, developing efficient and specific purification processes to remove fragment impurities is a core step in the successful development and commercialization of bispecific antibody drugs.
-
02【Case Analysis】Ion Exchange and Hydroxyapatite Media in ADC Purification
Antibody-Drug Conjugates (ADCs) are a novel class of biopharmaceuticals that combine monoclonal antibodies with cytotoxic drugs via chemical linkers, offering the dual advantages of high targeting specificity and potent cytotoxicity in tumor tissues.
-
03【Case Analysis】What to Do When Bispecific Antibody Aggregates Exceed Limits? Three Key Purification Technologies to Help You Overcome the Challenge
In the biopharmaceutical field, bispecific antibodies (BsAbs) are like a rising star, capturing the attention of researchers and companies alike. By simultaneously binding two different antigens or epitopes, they offer unique therapeutic advantages—such as precise tumor cell targeting and reduced side effects—making them a major focus of current R&D.